Update shared on29 Jul 2025
Fair value Decreased 15%CureVac's analyst price target was revised downward, primarily reflecting a modest improvement in future P/E while profitability remained stable, resulting in a new target of $5.35.
What's in the News
- BioNTech SE has agreed to acquire CureVac N.V. in a stock-for-stock deal, valuing CureVac at approximately $1.25 billion.
- CureVac shareholders will receive around $5.46 in BioNTech ADSs per CureVac share, with the final exchange ratio subject to a collar mechanism based on BioNTech’s share price.
- Upon completion, CureVac will become a wholly owned subsidiary of BioNTech, with its research and manufacturing site in Tübingen integrated into BioNTech’s operations, and CureVac shareholders expected to own 4–6% of BioNTech.
- Major CureVac shareholders representing 50.08% of shares, including dievini Hopp BioTech, KfW, and board members, have committed to tender their shares and vote in favor of the transaction.
- The transaction has unanimous board approval from both companies and is subject to a minimum 80% acceptance threshold by CureVac shareholders and regulatory approvals.
Valuation Changes
Summary of Valuation Changes for CureVac
- The Consensus Analyst Price Target has significantly fallen from $6.31 to $5.35.
- The Future P/E for CureVac has fallen slightly from 91.17x to 88.34x.
- The Net Profit Margin for CureVac remained effectively unchanged, at 10.54%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.